finance.yahoo.com ·
1 top wall street analyst 203500008
Topic context
This topic has been covered 258912 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article discusses CRISPR Therapeutics' stock performance and pipeline progress. The primary commercial mechanism is the potential revenue from CTX611 (anticoagulant) and Casgevy (gene therapy). No immediate price or supply shock; impact is speculative based on clinical trial outcomes and market adoption. Sector: PHARMA_BIOTECH. No concrete near-term commercial mechanism beyond analyst projections.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- CRISPR Therapeutics stock up 56% over past year vs S&P 500 30%.
- Analyst average price target $82.55, 51% upside; Piper Sandler target $110.
- Awaiting clinical data for anticoagulant CTX611 targeting $20B market.
- Approved product Casgevy (with Vertex) expected to gain traction despite slow initial sales.
CRISPR Therapeutics may see limited upside from CTX611 clinical data and Casgevy sales traction over the next 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort